Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation - Takeaways - DentalSpire

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

  • By

  • Kristina Maas-Bauer

  • Thomas Meyer

  • Mehtap Yücel

  • Maria Garofalaki

  • Stefanie Koßmann

  • Francesca Biavasco

  • Memnon Lysandrou

  • Miguel Waterhouse

  • Tobias Feuchtinger

  • Dietmar Pfeifer

  • Florian Ingelfinger

  • Tobias Wertheimer

  • Justus Duyster

  • Jae Sook Ahn

  • Robert J. Soiffer

  • Jürgen Finke

  • Ralph Wäsch

  • Alexandros Spyridonidis

  • Dennis Dong Hwan Kim

  • Claudia Wehr

  • Robert Zeiser

  • April 3, 2026

Share

  • 1

    Relapse of acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (allo-HCT) is influenced by genetic alterations and mutational dynamics.

  • 2

    68% of patients showed genetic instability, with common mutations in FLT3-ITD, NRAS, and KRAS, while founding mutations like DNMT3A were typically retained.

  • 3

    Clonal evolution patterns in relapsed AML included constant, linear, branching, and parallel evolution, but these patterns did not affect survival outcomes.

  • 4

    Early relapse (≤ 6 months) significantly increased mortality risk compared to late relapse, regardless of the mutational evolution model.

  • 5

    The study emphasizes the importance of longitudinal molecular monitoring for therapeutic decision-making in AML patients post-transplant.

Original Source(s)

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

  • by Kristina Maas-Bauer, Thomas Meyer, Mehtap Yücel, Maria Garofalaki, Stefanie Koßmann, Francesca Biavasco, Memnon Lysandrou, Miguel Waterhouse, Tobias Feuchtinger, Dietmar Pfeifer, Florian Ingelfinger, Tobias Wertheimer, Justus Duyster, Jae Sook Ahn, Robert J. Soiffer, Jürgen Finke, Ralph Wäsch, Alexandros Spyridonidis, Dennis Dong Hwan Kim, Claudia Wehr, Robert Zeiser

  • April 3, 2026

Related Content

Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report

Single dose of 5 Gy can damage erythrocytes and consequently induces lymphocyte depletion in spleen and circulating blood